Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33 results about "Osmotic concentration" patented technology

Osmotic concentration, formerly known as osmolarity, is the measure of solute concentration, defined as the number of osmoles (Osm) of solute per litre (L) of solution (osmol/L or Osm/L). The osmolarity of a solution is usually expressed as Osm/L (pronounced "osmolar"), in the same way that the molarity of a solution is expressed as "M" (pronounced "molar"). Whereas molarity measures the number of moles of solute per unit volume of solution, osmolarity measures the number of osmoles of solute particles per unit volume of solution. This value allows the measurement of the osmotic pressure of a solution and the determination of how the solvent will diffuse across a semipermeable membrane (osmosis) separating two solutions of different osmotic concentration.

Bicarbonate physiological balanced solution and preparation method thereof

The invention discloses a bicarbonate physiological balanced solution which belongs to the field of infusion preparations and is prepared form the following raw materials: sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate, glucose, citric acid and trisodium citrate. All the raw materials are accurately weighed according to corresponding portions, and dissolved in water for injection; the volume is determined; medical standard CO2 gas is introduced; the pH value is adjusted; and the solution is filtered, filled, packed, sterilized, labeled and then stored at room temperature. The solution has the advantages that ion components and a penetration concentration are similar to those of extracellular fluid and have physiological performance. The balanced solution is suitable for supplementing the extracellular fluid by injection, intravenous drip or oral administration, has an adjustment function for acid-base balance, and is also used as a surgical washing fluid or buffering solution.
Owner:曾因明 +1

Pressurized Forward Osmosis Process and System

A pressurized forward osmotic separation process is disclosed. Generally there are two processes described. One process involves the concentration of a target solute in the first solution; the other process involves the extraction of a solvent from a first solution both by a second solution comprising of water and soluble gas or water, soluble gas, and a compound by creating an osmotic concentration gradient across the semi permeable membrane. The first solution is under pressure from an inert gas and the second solution is under pressure from a soluble gas with equal system pressures greater than 1 atmosphere. The increase or decrease of partial pressure of the soluble gas in the second solution increases or decreases the chemical potential of the second solution to achieve different solution properties. The soluble gas may be carbon dioxide and the compound may be magnesium hydroxide.
Owner:LEHIGH UNIVERSITY

Rh group incompatibility therapeutic apparatus

The invention relates to an Rh group incompatibility therapeutic apparatus in the field of medical science. The Rh group incompatibility therapeutic apparatus is characterized in that rhesus monkey red blood cells containing human common Rh antigen are alternately washed by PB lysate with the osmotic concentration of 25 and 35mmol / L, ghost cells dialyzed with hemoglobin, retaining Rh antigenicity and capable of adsorbing an Rh antibody are prepared and fixed to agarose with special concentration together with the Rh antibody prepared by immunology according to a specific ratio, the agarose is placed into a cylindrical adsorber made of high-biocompatibility materials, antibody valence from high to low and agarose concentration from low to high are formed from a sample inlet end to a sample outlet end, the ghost cells are uniformly distributed, red blood cell destruction products of patients suffering from group incompatibility can be effectively intercepted by the agarose with gradually increased special concentration and gradually decreased molecular micropores at the sample inlet end and the sample outlet end and a mesh screen at an outlet of the adsorber, and a novel therapeutic method for maternal fetal Rh group incompatibility does not remove plasma components and avoids toxic and side effects.
Owner:ATTACHED OBSTETRICS & GYNECOLOGY OSPITAL MEDICALCOLLEGE ZHEJIANG UNIV +1

Detection method for osmotic concentration of vehicle fuel tank welding point and connector

The invention discloses a method for detecting the osmotic concentration of automobile fuel tank welding points and joints. The method comprises the following steps: firstly, placing the automobile fuel tank in a testing box, heating the testing box until the temperature of the air in the box reaches 36 DEG C, and opening an internal recycling air blower so as to ensure that the temperature field in the box is uniform and kept for 1 hour at a temperature of 36 DEG C; secondly, opening an external recycling air inlet and an external recycling air outlet on the wall of the testing box so as to ensure that the fuel steam hydrogen helium concentration is stabilized to be 3ppmC; and thirdly, starting a flame electrical detector, the air in the testing box enters the detector from a sampling port, and returns to the testing box from a sample return port; sleeving a Teflon air pipe on the sampling port, placing the pipe port of the Teflon air pipe at a point 5 millimeters above a welding point or a joint so as to measure the fuel steam hydrogen helium concentration of the point; and comparing the fuel steam hydrogen helium concentration with a background concentration so as to judge a specific position with larger osmotic quantity. The detecting method directly samples each welding point or each joint, and can quickly lock the specific position with overproof osmotic quantity.
Owner:YAPP AUTOMOTIVE PARTS

Blood purification therapeutic apparatus for treating mother-fetus Rh blood group incompatibility

The invention relates to a blood purification therapeutic apparatus for treating mother-fetus Rh blood group incompatibility in the medical field. The blood purification therapeutic apparatus is characterized in that PB lysates with osmotic concentrations of 25 mmol / L and 35 mmol / L respectively are prepared; rhesus red blood cells containing a common Rh antigen of human red blood cells are alternately washed to prepare ghost cells which dialyze hemoglobin but retain the Rh antigen and can effectively adsorb an Rh antibody; purifying agents with the ghost cell concentration of 95% are prepared by using agarose, with the concentrations of 0.9%, 1.0%, 1.1%, 1.2% and 1.3% respectively, molten at 100 DEG C and then thermally insulated at 42 DEG C; from high concentration to low concentration of the agarose, 55-65ml of the purifying agents are sequentially added into a cylindrical container made of a highly-biocompatible material so as to form an adsorber in which ghost cells in the purifying agents are uniformly distributed from the sample inlet end to the sample outlet end, but agarose concentration gradually increases from the sample inlet end to the sample outlet end; the adsorber is used for clearing away the Rh antibody in plasma of a filtering purifier and macromolecular pathogenic substances generated by destroyed red blood cells so as to treat a hemolytic disease caused by the Rh blood group incompatibility.
Owner:ATTACHED OBSTETRICS & GYNECOLOGY OSPITAL MEDICALCOLLEGE ZHEJIANG UNIV +1

Synchronic monitor system for drug delivery induced by ultrasound and the method thereof

The present invention provides a synchronic monitor system using real-time ultrasound image to monitor the permeable concentration of the targeted tissue for drug delivery induced by ultrasound. The drug delivery is performed by using a first ultrasound apparatus to emit a first ultrasound to a blood vessel of the targeted tissue to allow a drug passing through the blood vessel into a lesion zone. The synchronic monitor system comprises a second ultrasound apparatus and software. The second ultrasound apparatus has a transducer, and the transducer is used to emit a second ultrasound to the blood vessel to determine several information of the blood flow. The software is installed in the second ultrasound apparatus to collect the information of the blood flow, and calculate an extravasation of the drug in the lesion zone according to the information of the blood flow via a first equation. The present invention discloses a method using the same.
Owner:NATIONAL YANG MING UNIVERSITY

Adsorption herapeutic apparatus for maternal-fetal blood group incompatibility

The invention relates to an adsorption herapeutic apparatus for maternal-fetal blood group incompatibility, relating to the medical field. The apparatus is characterized by comprising following steps: utilizing PB of 25 and 35 mmol/L as lysate, fully washing Rh positive O-type erythrocytes and cleaning them with normal saline to make ghost cells with dialysis of ferrohemoglobin and antigen performance capable of effectively absorbing Rh antibodies, utilizing 0.9%, 1.0%, 1.1%, 1.2% and 1.3% of agarose which is melt at 100 DEG C and kept in 56 DEG C to make adsorbents of 95% of ghost cell concentration, orderly taking 55-65ml according to ghost cell concentration from high to low to be added into a cylindrical container made by material with high biocompatibility so that an absorber enabling adsorbents from a sample inlet end to a sample outlet end to form uniform distribution of ghost cells and agarose concentration from low to high, using the above to clear Rh anti-bodies in plasmas filtered by the absorber and macromolecule disease-causing substances generated by destroyed erythrocyte such that the treatment purpose of preventing Rh anti-bodies of pregnant women from entering fetus blood and lightening condition is achieved.
Owner:ATTACHED OBSTETRICS & GYNECOLOGY OSPITAL MEDICALCOLLEGE ZHEJIANG UNIV +1

Method of synergetic minimization of negative impact caused by flights on human health

ActiveUS20210220414A1Suppress pathogenic bacterial activityNot cause any side effectSalicyclic acid active ingredientsDispersion deliveryAviationFluid replacement
This invention is referred to the field of medicine, namely preventative treatment, and may be used as a means of synergetic minimization of negative impact of flights on human health (brain, stomach, lungs, blood vessels, heart etc.) with application of known substances and medicines with newly discovered pharmacological properties in new conditions. The ultimate technical solution of this invention would be synergetic minimization of negative impact of flying on human health without foot swelling, belching, jet-lag, tiredness and fatigue etc. The claimed technical result is achieved by the method of synergetic minimization of negative impact of air flights on human health, including consumption of substances that improve osmotic concentration of blood plasma, in the form of oral rehydration solution, split into two intakes as a minimum, first intake in the amount of at least 0.3 liters up to 1 liter before boarding and further during the flight from half an hour to 2 hours at least 0.3 liters to 1 liter and on as-needed basis.
Owner:LURYE ARMAN ZHENISOVICH

Buried type agricultural irrigation system capable of adjusting osmotic concentration

The invention relates to a buried type agricultural irrigation system capable of adjusting osmotic concentration. The irrigation system comprises a main pipeline, a secondary pipeline, a drainage portand a regulating valve, wherein the drainage port is formed in the secondary pipeline, the regulating valve is arranged on the joint between the drainage port and the secondary pipeline, a first semi-permeable membrane is arranged on the joint between the main pipeline and the secondary pipeline, a second semi-permeable membrane is arranged on the joint between the secondary pipeline and the drainage port, the regulating valve is connected with a regulating water tank, the regulating water tank regulates the concentration of an aqueous solution in the secondary pipeline, the first semi-permeable membrane is used for taking water from the main pipeline, the second semi-permeable membrane is used for irrigating the outside through the drainage port, the irrigation system further comprises amonitoring system, the monitoring system further comprises a flow instrument, a first flow velocity meter, a second flow velocity meter, a third flow velocity meter and a control meter, the first flow velocity meter, the second flow velocity meter and the third flow velocity meter measure the water velocities on the first semi-permeable membrane, second semi-permeable membrane and regulating valve respectively, the flow instrument detects the amount of water discharged from the drainage port, and the control meter controls the regulating valve to adjust the irrigation speed and irrigation amount of the irrigation system.
Owner:张振花

Plant cold-resisting antifreezing agent

InactiveCN107027835AStrange photosynthesisUnique adjustmentPlant growth regulatorsBiocideBiotechnologyPotato starch
The invention provides a plant cold-resisting antifreezing agent. The plant cold-resisting antifreezing agent is prepared from, by weight, 3-9 parts of corn juice, 6-12 parts of ephedra extracting solution, 8-12 parts of rapin, 4-7 parts of silver thiosulfate, 4-6 parts of monopotassium phosphate, 2-4 parts of paclobutrazol, 0.5-1 part of lysine, 0.5-0.8 part of cysteine, 3-6 parts of garlic filter liquor, 0.5-1 part of maltose, 1-2 parts of potato starch, 2-3 parts of algal polysaccharides, and 2-3 parts of polylactic acid. According to the plant cold-resisting antifreezing agent, cysteine is added for resisting and destroying crop germs; lysine has unique photosynthesis and regulating effect to crops; maltose and potato starch added for rapidly improving content of sugar in a plant cell, so that the cell osmotic concentration is improved, the water potential is reduced, and the water retaining capacity is increased; meanwhile, the cell heat is added, freezing in the cell and the cell frozen dehydration are avoided; thus the low-temperature resistance and cold resistance of the plant are improved.
Owner:广西棕海园林工程有限公司

System for measuring properties of mass transport behavior in membrane and solutions

Disclosed is a system for measuring mass transfer in a membrane and solutions. The system includes: a membrane module 10 including a feed solution reservoir 11 accommodating a feed solution f, a draw solution reservoir 13 accommodating a draw solution d whose osmotic concentration is higher than that of the feed solution f, and a holder 15 supporting a semipermeable membrane m arranged between the feed solution reservoir 11 and the draw solution reservoir 13 and whose performance is to be measured; a feed solution storage tank 20 storing the feed solution f; and a feed solution supply pump 30 supplying the feed solution f from the feed solution storage tank 20 to the feed solution reservoir 11 at a fixed flow rate corresponding to a water flux WF across the membrane m such that the water flux WF is maintained constant.
Owner:KOREA UNIV RES & BUSINESS FOUND

Maternal-fetal blood group incompatibility adsorption therapy device

The invention relates to an adsorption herapeutic apparatus for maternal-fetal blood group incompatibility, relating to the medical field. The apparatus is characterized by comprising following steps: utilizing PB of 25 and 35 mmol / L as lysate, fully washing Rh positive O-type erythrocytes and cleaning them with normal saline to make ghost cells with dialysis of ferrohemoglobin and antigen performance capable of effectively absorbing Rh antibodies, utilizing 0.9%, 1.0%, 1.1%, 1.2% and 1.3% of agarose which is melt at 100 DEG C and kept in 56 DEG C to make adsorbents of 95% of ghost cell concentration, orderly taking 55-65ml according to ghost cell concentration from high to low to be added into a cylindrical container made by material with high biocompatibility so that an absorber enabling adsorbents from a sample inlet end to a sample outlet end to form uniform distribution of ghost cells and agarose concentration from low to high, using the above to clear Rh anti-bodies in plasmas filtered by the absorber and macromolecule disease-causing substances generated by destroyed erythrocyte such that the treatment purpose of preventing Rh anti-bodies of pregnant women from entering fetus blood and lightening condition is achieved.
Owner:ATTACHED OBSTETRICS & GYNECOLOGY OSPITAL MEDICALCOLLEGE ZHEJIANG UNIV +1

Detection method for osmotic concentration of vehicle fuel tank welding point and connector

The invention discloses a method for detecting the osmotic concentration of automobile fuel tank welding points and joints. The method comprises the following steps: firstly, placing the automobile fuel tank in a testing box, heating the testing box until the temperature of the air in the box reaches 36 DEG C, and opening an internal recycling air blower so as to ensure that the temperature fieldin the box is uniform and kept for 1 hour at a temperature of 36 DEG C; secondly, opening an external recycling air inlet and an external recycling air outlet on the wall of the testing box so as to ensure that the fuel steam hydrogen helium concentration is stabilized to be 3ppmC; and thirdly, starting a flame electrical detector, the air in the testing box enters the detector from a sampling port, and returns to the testing box from a sample return port; sleeving a Teflon air pipe on the sampling port, placing the pipe port of the Teflon air pipe at a point 5 millimeters above a welding point or a joint so as to measure the fuel steam hydrogen helium concentration of the point; and comparing the fuel steam hydrogen helium concentration with a background concentration so as to judge a specific position with larger osmotic quantity. The detecting method directly samples each welding point or each joint, and can quickly lock the specific position with overproof osmotic quantity.
Owner:YAPP AUTOMOTIVE PARTS

Maternal rh blood type incompatibility blood purification treatment instrument

The invention relates to a blood purification therapeutic apparatus for treating mother-fetus Rh blood group incompatibility in the medical field. The blood purification therapeutic apparatus is characterized in that PB lysates with osmotic concentrations of 25 mmol / L and 35 mmol / L respectively are prepared; rhesus red blood cells containing a common Rh antigen of human red blood cells are alternately washed to prepare ghost cells which dialyze hemoglobin but retain the Rh antigen and can effectively adsorb an Rh antibody; purifying agents with the ghost cell concentration of 95% are prepared by using agarose, with the concentrations of 0.9%, 1.0%, 1.1%, 1.2% and 1.3% respectively, molten at 100 DEG C and then thermally insulated at 42 DEG C; from high concentration to low concentration of the agarose, 55-65ml of the purifying agents are sequentially added into a cylindrical container made of a highly-biocompatible material so as to form an adsorber in which ghost cells in the purifying agents are uniformly distributed from the sample inlet end to the sample outlet end, but agarose concentration gradually increases from the sample inlet end to the sample outlet end; the adsorber is used for clearing away the Rh antibody in plasma of a filtering purifier and macromolecular pathogenic substances generated by destroyed red blood cells so as to treat a hemolytic disease caused by the Rh blood group incompatibility.
Owner:ATTACHED OBSTETRICS & GYNECOLOGY OSPITAL MEDICALCOLLEGE ZHEJIANG UNIV +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products